Alterations in growth factor signaling pathways frequently accompany the development and maintenance of epithelial neoplasia. Transforming growth factor a (TGFa) and its epidermal growth factor receptor have been thought to play an especially important role in epithelial neoplasia. In this study, mice were derived genetically deficient (null) in functional TGFa expression and carrying the Tg.AC/v-Ha-rus transgene. The goals were to determine if (a) papillomagenesis was dependent on TGFa and (b) progression to malignancy was dependent on TGFa expression. Groups of male and female mice heterozygous or homozygous for the TGFa null allele and hemizygous for the Tg.AC transgene were treated twice weekly for 10 or 15 wk with doses of 12-0-tetradecanoylphorbol-13-acetate (TPA) known to produce papillomas in Tg.AC mice. Papillomas were readily induced in both male and female TGFa null mice. Malignant progression of papillomas was observed in all TGFa null treatment groups. Additionally. we examined the response of TGFa null mice to full thickness dorsal wounds, a stimulus known to promote papillomagenesis in Tg.AC mice. As in the TPA study, papillomas were induced in both male and female TGFa null mice. These studies indicate that TGFa is not required for the induction and maintenance of papillomas nor is it essential for the malignant conversion of papillomas in T g A C mice. Downloaded from . K, and Sasada R (1994). Recombinant human betacellulin. J. Biol. 44. Wong ST, Winchell LE McCune BK. Earp HS, Teixido' J, Massague' J, Herman B, and Lee DC (1989). The TGF-a precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction. Cell 56: 495-506. 62: 679-682. '.Client. 269: 9966-9973.
INTRODUCTION
Transforming growth factor a (TGFa), which acts by binding to and activating the epidermal growth factor re-. ceptor (EGFR), is a potent mitogenic polypeptide for many epithelial and mesenchymal cells, including skin keratinocytes (8, 27, 28, 39, 40, 44) . A member of the epidermal growth factor (EGF) family, TGFa is 35% identical to EGF (26) . Other mammalian members of the EGF family including EGF itself, amphiregulin (35) , betacellulin (34, 43) , and heparin-binding EGF-like growth factor (HB-EGF) (15) are also ligands for the EGFR. Depending on the target cell, members of the EGF family can stimulate or inhibit proliferation and affect a variety of cellular responses. These effects are thought to be mediated through binding to the EGFR, though the biological consequences produced by the various family members are not always equivalent (5, 6, 15, 28, 31) .
To examine the requirement for TGFa in epidermal tumorigenesis, TGFa null mice (23, 24) were crossed with homozygous Tg.AC transgenic mice carrying an activated v-Ha-ras gene (22) . TGFa null mice exhibit hair and eye abnormalities but are otherwise healthy (23) . The genetically initiated Tg.AC mice exhibit a normal dorsal skin morphology and physiology until exposed to a cutaneous wound, carcinogenic chemical, or tumor promoter such as 12-0-tetradecanoylphorbol-13-acetate ( P A ) . Such exposure results in the formation of epider-ma1 papillomas expressing the v-Ha-ras transgene (14, 22, 37) . TGFa nulflg.AC (v-Ha-ras) transgenic mice ..provide a unique opportunity to examine the role of TGFa in the process of tumor promotion.
We report here that papillomas develop in TGFa deficient/rg.AC mice following TPA exposure or wounding. 'hmors were capable of progressing to malignant squamous/spindle cell carcinomas. These results support the notion that TGFa is dispensable in epidermal tumorigenesis in Tg.AC mice but do not rule out the possibility that EGFR function is important.
METHODS

Anitnals.
Mice were housed 4/polycarbonate microisolator cage in facilities at the University of North Carolina-Chapel Hill according to standards of the American Association for Accreditation of Laboratory Animal Care. Mice were fed Prolab RMH 2000 mouse chow (PMI Feeds, St. Louis, MO) and water ad Zibitzcm and maintained at 70°F on a 12-hr lighddark cycle.
TGFa null mice were generated by homologous recombination in C129 embryonic stem cells (23) . The TGFa null mutation was then introduced into the C57BL/ 6 background by interbreeding. Tg.AC mice (National Institute of Environmental Health Sciences [NIEHS], Research Triangle Park, NC) contain a transgene consisting of a 980-bp zeta-globin promoter fused to a v-Ha-ras gene (containing activating mutations at codons 12 and 59) linked to the SV-40 3' polyadenylatiodsplice sequence on an FVB/N background (22) . To produce the target population, TGFa homozygous null mice were first bred to Tg.AC mice homozygous for the transgene. Re-562 0192-6233/98$3.00+$0.00 sulting F, females, heterozygous for TGFa and hemizygous for the Tg.AC transgene, were then bred to TGFa null males. Offspring were genotyped for the TGFa null allele and the Tg.AC transgene. Mice not carrying the Tg.AC transgene were not used in this study.
Genoryping. TGFa null mice were identified by their characteristic wavy fur and curly whiskers, which is 100% correlated with the homozygous mutant genotype (23) . Presence of the Tg.AC transgene was determined by DNA blot analysis of tail DNA and confirmed by polymerase chain reaction (PCR) amplification as follows. DNA was isolated from tail tissue by Proteinase K (Boehringer Mannheim Corp., Indianapolis, IN) digestion and quantified on a Beckman DU-600 UV-VIS spectrometer. Samples (250 ng) were then amplified in a total volume of 50 p1 containing 1 X PCR buffer (Promega, Madison, WI) (50 m f KCl, 10 mi Tris-HC1, pH 9.0 [25"C], 0.1% Triton X-100), 4 mi MgCl,, 0.4 mhf dNTPs, 10-15 pmol each primer, and 1.25 units Taq DNA polymerase (Promega). The amplification protocol consisted of a 1-min denaturation at 94"C, followed by 30 cycles of a 30-sec denaturation at 94"C, 30-sec annealing at 5O"C, and 30-sec elongation at 72°C. The sequence of the 5' transgene primer was 5'-TGG ACA AAC TAC CTA CAG-3', and the sequence of the 3' antisense primer was 5'-AAT TCT GAA GGA AAG TCC-3'. These sequences are directed toward the transgene SV-40 3' polyadenylation sequence and span an intervening sequence. Amplification products were visualized on 2% agarose gels stained with ethidium bromide and photographed with Polaroid type 57 high-speed film. Transgene amplG fication yielded a 279-bp product for genomic DNA and a 214-bp product for RNA. As a control, glyceraldhyde 3-phosphate dehydrogenase (GAPDH) was also amplified using a 5' sense primer (5'-7TC ATT GAG CTC AAC TAC AT-3') and a 3' antisense primer (5'-GTG GCA GTG ATG GCA TGG AC-3'). The GAPDH amplification product was -490-500 bp.
Cheriiical Carcinogenesis/Treatnieiit of Mice with TPA or Acetone. Groups of male and female mice heterozygous or homozygous for the TGFa null allele and hemizygous for the Tg.AC transgene were treated with doses of TPA (Sigma Chemical Co., St. Louis, MO) known to produce papillomas in Tg.AC mice. Dorsal skin of approximately 8-wk-old mice was shaved and then treated with TPA dissolved in 200 pl acetone. Animals were dosed twice weekly for 10 wk with 2.5 pg TPA (4.1 nmole) or twice weekly for 15 wk with 1.5 pg TPA (2.4 nmoles). Control mice received 200 ~1 acetone vehicle for the corresponding time period. Mice were observed twice weekly for up to 64 wk. Papilloma and malignancy development were recorded at each observation. Papillomas had to reach 1 mm in size and persist for at least 3 wk to be counted as positive. Because individual papillomas were not mapped, this criterion applied only to the first papillomas to appear. Mice were euthanatized prior to the termination of the experiment if they appeared moribund or if they harbored papillomas that had converted to malignancy. Papilloma samples were-snap frozen in liquid nitrogen andlor fixed for 24 hr in 10% neutral buffered formalin with subsequent immersion in 70% ethanol. Fixed tissues were paraffin embedded, and 4-6-pm sections were stained with hematoxylin and eosin.
Wound Healing. Control mice from the TPA dosing regimen as well as other untreated mice were utilized for studies of wound healing. Mice, either 24 or 37.5 wk of age (on average), were anesthetized with metophane (methoxyfluorane, Pitman-Moore, Washington Crossing, NJ), and their dorsal skin was shaved with electric clippers. After cleansing the dorsal skin with 70% ethanol, a full thickness incision, 2.5 cm long and parallel and left of midline, was made on each mouse. Incisions were immediately closed with 5-7 wound clips. Wound clips were removed 7 days later. Mice were observed twice weekly for up to 54 wk. Papilloma development was recorded at each observation. Dorsal skin was shaved as needed for papilloma observations along the wound line.
Isolation of Total RNA. To examine expression of the Tg.AC transgene, bone marrow was isolated from selected mice by flushing both femurs with phosphate-buffered saline. Marrow was then pelleted and stored at -80°C. RNA was extracted utilizing TriReagent (Molecular Research Center, Cincinnati, OH) following the manufacturer's protocol (1, 2) . The cells were resuspended in 1 ml of TriReagent and homogenized with a polytron homogenizer (Brinkmann Instrument Co., Westbury, NY). Following a 5-min incubation at room temperature, chloroform was added (0.2 ml:l ml TriReagent), and the samples were thoroughly mixed. Samples were incubated 2-3 min at room temperature and then centrifuged at 12.000 X g for 15 min at 4°C. The upper aqueous layer was removed, and 0.5 ml of isopropyl alcohol was added. Following a 30-min incubation at room temperature, the samples were centrifuged at 7,000 X g for 20 min at 4°C. The supernatant was removed, and the pellet was washed with 1 ml of 75% ethanol. The samples were centrifuged at 9,000 X g for 10 min at 4°C. The supernatant was removed, and the RNA pellet was allowed to air dry briefly. RNA was resuspended in sterile 0.1% diethylpyrocarbonate-treated water and stored at -80°C. RNA was quantified on a Beckman DU 600 spectrophotometer prior to use.
Transgene Reverse Transcription-PCR Ainplijication. Total RNA (1 bg) was combined with 4.5 units of Ah4V reverse transcriptase in a 20-1-1.1 reaction volume containing 7 mi MgCl,, 0.5 pg oligo [dT],, primer, 1 m~ each dATP, dCTP, dGTP, and dmP, 16 units of RNasin, and 1 X magnesium-free reaction buffer (Promega, 50 mi KCl, 10 mi Tris-HCI, pH 9.0, and 0.1% Triton X-100).
Reaction mixtures were incubated at 42°C for 60 min in a DNA thermal cycler (Perkin Elmer Corp., Norwalk, CT). The enzyme was heat inactivated at 99°C for 5 min and then cooled to 4°C. A portion of this cDNA solution was amplified using PCR for the Tg.AC transgene (under the final conditions described above) and mouse betaglobulin-2 (MB2) (at a final MgC1, concentration of 4 mr). The MB2 sense primer was 5'-GAC TGG TCT 'ZTC TAT ATC CTG G-3', and the antisense primer was 5'-ClT TCT GCG TGC ATA AAT TG-3'. These primers generate a product -217 bp in length.
Statistics. Statistical analysis of the data was per- 
RESULTS
High Dose TPA (2.5 pg)
Groups of male and female mice (4-1 1 each) that were hemizygous for the Tg.AC v-Ha-ms transgene and either heterozygous or null for TGFa were treated topically with 2.5 pg TPA or vehicle twice weekly for 10 wk. Resulting papillomas were counted twice weekly up to a maximum of 50/mouse. Female and male mice, both heterozygous and null for TGFa, developed epidermal papillomas on the dorsal skin treatment area in response to this dose of TPA (Table I) . Average number of papillomas per mouse are based on the maximum number of papillomas that formed on each mouse as of week 26 or by the time of death. By 26 wk, TPA-treated mice heterozygous for TGFa developed 40.6 and 44 papillomas/ mouse in female and male mice, respectively, whereas TGFa null mice had only 37.8 and 34.8 papillomas/ mouse, respectively. TGFa null mice of both sexes developed fewer papillomas than did their counterpart heterozygotes, but the differences were not significant. Animals treated with vehicle alone developed 0.2 papillomas/mouse or none ( Table I) .
A time course of papilloma development following treatment with 2.5 pg TPA is shown in Fig. 1 . The calculated values represent the average number of papillomas per TPA dose group at each observation. The maximum papilloma count achieved for each mouse was retained in the mean calculation, even if a regression in the papilloma number occurred or if a mouse died or was euthanatized. A small but significant difference (p C 0.05) was observed as a longer latency to first papilloma formation in male TGFa null mice relative to male TGFa heterozygotes. The distribution of papilloma responses in TPA-treated mice is summarized in Fig. 2a .
Low Dose TPA
The 2.5-pg dose of TPA had an adverse effect on the mice, either directly or because of the resultant tumor burden, and hence only 12 of 36 TPA-treated mice (33.3%) survived to week 26. Accordingly, we performed a subsequent experiment using a lower dose of TPA, not only to reduce the apparent toxicity to the animals but also to reduce the number of induced papillomas to allow better quantitation and comparison. Groups of 9-17 male and female mice of each TGFa genotype were treated topically with 1.5 pg of TPA (or vehicle control) twice weekly for 15 wk. As with the higher dose, female and male mice of both TGFa genotypes developed epidermal papillomas in the treatment area (Table 11 ). This lower TPA dose led to a much higher 26-wk survival rate (42/ 56 mice [75%]) and a lower tumor load ( Fig. 2b) . At 26 wk, TPA-treated female and male mice heterozygous for TGFa developed 20.6 and 18.2 papillomas/mouse, respectively, whereas female and male TGFa null mice had only 17.7 and 7.3 papillomadmouse, respectively. The time course for papilloma development (Fig. 3) shows a slight but not significant delay in papilloma formation in TGFa null mice. As with the higher TPA dose, TGFa null mice appeared to develop fewer papillomas than did the sex-matched heterozygotes, especially when comparing the male responses. However, because of the variability in responses (Fig. 2b) , the differences were notsignificant.
Conversioii to Malignartcy
To determine if malignant progression of papillomas is impaired in the absence of TGFa, mice were monitored up to 64 wk from the start of TPA dosing. At both TPA doses and in all TGFa null groups with animals surviving at least 25 wk, malignant conversions of papillomas were observed (Table 111 ) and confirmed histologically.
WOl411d Healing
Tg.AC mice form papillomas at the site of wounds (22) . To explore the necessity for TGFa in wound-induced tumorigenesis, vehicle-treated control mice from the high dose TPA study were removed 20 wk after dosing began, and full-thickness dermal incisions were made. These mice and a second group of untreated mice were monitored twice weekly for papilloma development. As in the previous studies with TPA, TGFa null mice developed papillomas. Heterozygous TGFcl mice developed an average of 1.5 papillomas/mouse, whereas TGFa null mice developed 1.4 papillomas/mouse (Table IV) . No significant difference was detected between these 2 groups, although very few papillomas appeared.
Analysis of Traitsgeite Expression
Over time, Tg.AC mice spontaneously develop transgene-dependent papillomas on their mouths, urogenital region, and foot pads (37) . However, of 182 bitransgenic mice created for this study, 16 remained papilloma free over their life span. This effect was litter dependent in many cases. Although not constitutively expressed in skin, the Tg.AC transgene is expressed at low levels in the bone marrow. To confirm Tg.AC transgene expression in our cohort of mice, bone marrow was isolated from a selection of mice at terminal euthanasia. Marrow RNA was reverse transcribed, and the resulting cDNA was amplified for the transgene using transgene-specific primers. Results indicated variable expression of the transgene consistent with the phenotype (data not presented). Mice displaying a stronger response to promotion stimuli (TPA and wounding) also displayed a qualitatively stronger reverse transcription (RT)-PCR product; conversely, lesser responders yielded a weaker amplification product. One mouse showing no response to TPA and no spontaneous papillomas yielded no RT-PCR amplification product, despite testing positive for the presence of transgene DNA. These results suggest that the transgene was silenced in some hemizygous mice in a manner unrelated to the presence or absence of TGFa.
DISCUSSION
TGFa production has been associated with human tumors and tumor cell lines (7) , and its targeted overexpression leads to accelerated tumorigenesis and hyperplastic phenotypes in vivo (17, 18, 29, 32, 33, 41) . A wealth of evidence supports a role for TGFa in the promotion phase of multistage skin carcinogenesis (9, 13, 16, 21), possibly by stimulating necessary proliferation. A potential link between TGFa and the promoting effect of wounding on initiated NMRI mouse skin has been prpposed (13), whereas both wounding and chemical promotion elevated TGFa mRNA levels in the epidermis of SENCAR mice (21) . An upregulation of TGFa and the loss of a negative-feedback mechanism on the EGFR is associated with TPA-induced hyperplasia in mouse skin (16). A TPA-associated increase in TGFa has also been detected histologically in skin papillomas and squamous cell carcinomas (30) . In addition, loss of TGFa or abrogated signaling through EGFR has resulted in an inhibition of tumorigenesis (1 1). These reports suggest a potentially important TGFa-dependent mechanism for the sustained cell proliferation necessary in skin tumor promotion. In contrast to these results is a report indicating that TGFa is not essential for epidermal hyperplasia, which suggests that another EGF family member(s) may be involved (10).
Epidermal papillomas in Tg.AC mice arise from the clonal expansion of v-Ha-ras transgene-expressing follicular epithelial cells (14). Mice with a deficiency in TGFa display a characteristic abnormal hair follicle morphology (23) . It was of interest to determine whether mouse skin papillomas could be induced in mice deficient (null) in TGFa expression while carrying the Tg.AC transgene. Two goals were (a) to determine if papillomas could be induced in the derived genotype and (b) if papillomas could be induced, to determine whether they were capable of progression to malignancy in the absence of TGFa expression.
Papillomas were readily induced in both male and female TGFa null mice that were hemizygous for the v-Ha-ras transgene following twice weekly treatment with TOXICOLOGIC PATHOLOGY 1.5 or 2.5 pg of TPA. Although differences in the average number of papillomas per mouse generated within each dosing group were not significant, a consistent trend was noticed whereby TGFa null mice generated fewer papillomas. Progression of papillomas to malignancies was observed in all treatment groups. Similarly, no significant differences in the numbers of papillomas/mouse were found between hemizygous Tg.AC mice homozygous and heterozygous for the TGFa null allele after a full thickness wound. An increase in time to first papilloma was seen in all dosing groups for TGFa null mice relative to sexmatched TGFa heterozygotes. However, this increase in time was significant only when comparing the male mice treated with the higher dose of TPA. Similar delays in the appearance of papillomas produced by TGFa-deficient keratinocytes (10) or skin grafts (12) have been reported. Our findings may support the suggestion that TGFa regulates tumor growth during certain stages in the tumorigenic process (10).
Transgene expression in the bone marrow was variable but was correlated with tumor burden. Several litters of mice did not develop the spontaneous papillomas found in mice carrying the v-Ha-ras transgene, even up to 2 yr of age. This resistance to papillomagenesis may be due to the interbreeding of the Tg.AC mouse with the more 37 .5 3 3 113 (33) resistant C57BW6 (TGFa null) mouse. C57BL/6 mice have been resistant to skin tumor promotion by TPA (20) . Subsequent to the termination of this experiment, a nonresponding phenotype within the Tg.AC mouse strain was identified. These mice do not exhibit the phenotypic papilloma response to tumor-inducing stimuli typified by the traditional Tg.AC mouse. This nonresponder phenotype has been associated with the loss of a 2-kb band on Southern blot analyses of ButnHI cleaved genomic DNA (E Sistare, FDA, personal communication). The homozygous Tg.AC mice used to establish the bitransgenic lineage utilized in this experiment predate the observance of the Tg.AC nonresponder phenotype. It is unlikely, therefore, that the nonresponding bitransgenic mice were the result of the Tg.AC nonresponder phenotype. If the nonresponding Tg.AC phenotype was involved, it would not affect the overall observation that TGFa null/Tg.AC , bitransgenic mice are capable of developing papillomas and malignancies. An explanation for the nonresponding phenotype is under examination.
These studies indicate that TGFa is not required for the induction and maintenance of papillomas nor for their malignant progression in Tg.AC mice. The activity of other ligands specific for the EGFR possibly are replacing the requirement for TGFa in this skin carcinogenesis model. This hypothesis is supported in part by results of a previous study (lo), in which v-rusHa induced phenotypic changes in TGFa null and wild-type keratinocytes in vitro and itt vivo. As reported, amphiregulin, HB-EGF, and betacellulin were all upregulated in squamous papillomas generated by grafting TGFa null (-/-) v-rusHa keratinocytes onto nude mice. Additional epidermal expression of EGFR ligands has also been reported. HB-EGF mRNA has been detected in the skin of adult pigs by RT-PCR (42) and in pig wound fluid (25) . Amphiregulin expression is upregulated in the benign hyperproliferative skin disease psoriasis (3), and betacellulin .' poly(A)+ RNA has been isolated from the epidermis of by grants NIEHS T32 ES07126 (to M.C.H.) and CA43793 (to D.C.L.).
